Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Grants Orphan Drug Designation for OCU400 for NR2E3 Mutation-Associated Retinal Degenerative Disease Treatment

americanpharmaceuticalreviewFebruary 15, 2019

Tag: FDA , Orphan Drug , OCU400 , Retinal Degenerative Disease

PharmaSources Customer Service